Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,936 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Wang Y, Jiang C, Dong X, Chen M, Gu Q, Zhang L, Fu Y, Pan T, Bi Y, Song W, Xu J, Lu W, Sun X, Ye Z, Zhang D, Peng L, Lin X, Dai W, Wang Q, Yang W. Wang Y, et al. Among authors: zhang l, zhang d. Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15596. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38618970
Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial.
Lu J, Fu L, Li Y, Geng J, Qin L, Li P, Zheng H, Sun Z, Li Y, Zhang L, Sun Y, Chen D, Qin G, Lu W, Guo Y, Zhang Y, Liu H, Zhang T, Zou J. Lu J, et al. Among authors: zhang l, zhang t, zhang y. Diabetes Obes Metab. 2021 May;23(5):1111-1120. doi: 10.1111/dom.14314. Epub 2021 Jan 31. Diabetes Obes Metab. 2021. PMID: 33417292 Clinical Trial.
Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.
Zhu D, Gan S, Liu Y, Ma J, Dong X, Song W, Zeng J, Wang G, Zhao W, Zhang Q, Li Y, Fang H, Lv X, Shi Y, Tian H, Ji L, Gao X, Zhang L, Bao Y, Lei M, Li L, Zeng L, Li X, Hou X, Zhao Y, Hu T, Ge X, Zhao G, Li Y, Zhang Y, Chen L. Zhu D, et al. Among authors: zhang l, zhang q, zhang y. Lancet Diabetes Endocrinol. 2018 Aug;6(8):627-636. doi: 10.1016/S2213-8587(18)30105-0. Epub 2018 May 4. Lancet Diabetes Endocrinol. 2018. PMID: 29735394 Clinical Trial.
Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study.
Ji L, Sun N, Zhang Y, Zhang L, Shen S, Wang X, Li Q, Dong L, Ren W, Qi L, Li Y, Yan S, Cheng W, Kuang H, Li G. Ji L, et al. Among authors: zhang l, zhang y. Diabetes Obes Metab. 2020 Feb;22(2):158-166. doi: 10.1111/dom.13884. Epub 2019 Oct 24. Diabetes Obes Metab. 2020. PMID: 31512365 Clinical Trial.
Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial.
Yao J, Guo X, Sun L, Han P, Lv X, Zhang X, Mo Z, Yang W, Zhang L, Wang Z, Zhu L, Li Q, Yang T, Wang W, Xue Y, Shi Y, Lu J, Peng Y, Zhang F, Yan D, Wang D, Yu X. Yao J, et al. Among authors: zhang l, zhang f, zhang x. Curr Med Res Opin. 2022 Nov;38(11):1797-1806. doi: 10.1080/03007995.2022.2100652. Epub 2022 Jul 22. Curr Med Res Opin. 2022. PMID: 35833285 Clinical Trial.
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS).
Jia W, Ma J, Miao H, Wang C, Wang X, Li Q, Lu W, Yang J, Zhang L, Yang J, Wang G, Zhang X, Zhang M, Sun L, Yu X, Du J, Shi B, Xiao C, Zhu D, Liu H, Zhong L, Xu C, Xu Q, Liang G, Zhang Y, Li G, Gu M, Liu J, Yuan G, Yan Z, Yan D, Ye S, Zhang F, Ning Z, Cao H, Pan D, Yao H, Lu X, Ji L. Jia W, et al. Among authors: zhang l, zhang m, zhang f, zhang x, zhang y. Sci Bull (Beijing). 2021 Aug 15;66(15):1581-1590. doi: 10.1016/j.scib.2021.02.027. Epub 2021 Feb 16. Sci Bull (Beijing). 2021. PMID: 36654287 Free article. Clinical Trial.
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.
Zhang L, Zhang Y, Shen S, Wang X, Dong L, Li Q, Ren W, Li Y, Bai J, Gong Q, Kuang H, Qi L, Lu Q, Cheng W, Liu Y, Yan S, Wu D, Fang H, Hou F, Wang Y, Yang Z, Lian X, Du J, Sun N, Ji L, Li G; China Diabetes Prevention Program Study Group. Zhang L, et al. Among authors: zhang y. Lancet Diabetes Endocrinol. 2023 Aug;11(8):567-577. doi: 10.1016/S2213-8587(23)00132-8. Epub 2023 Jul 3. Lancet Diabetes Endocrinol. 2023. PMID: 37414069 Clinical Trial.
Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial.
Wang W, Yao J, Guo X, Guo Y, Yan C, Liu K, Zhang Y, Wang X, Li H, Wen Z, Wang X, Li S, Xiao X, Liu W, Li Z, Zhang L, Shao S, Ye S, Qin G, Li Y, Li F, Zhang X, Li X, Peng Y, Deng H, Xu X, Zhou L, Huang Y, Cao M, Xia X, Shi M, Dou J, Yuan J. Wang W, et al. Among authors: zhang l, zhang x, zhang y. Curr Med Res Opin. 2020 Jul;36(7):1107-1115. doi: 10.1080/03007995.2020.1761311. Epub 2020 May 12. Curr Med Res Opin. 2020. PMID: 32338063 Clinical Trial.
124,936 results
You have reached the last available page of results. Please see the User Guide for more information.